What is actually known about how GHK-Cu works?
Mechanism means the chain of physical events by which a molecule produces an effect. For GHK-Cu that chain has three links: the peptide binds copper, the complex interacts with cells, and the cells change what they produce. Each link has been studied, but the studies get progressively less definitive as you move along the chain, and the final link, whether any of this produces a measurable effect in a living human, has not been established.
Every finding below is labelled with the model it came from. A result in a dish of cells is a different kind of evidence from a result in an animal, which is different again from a result in a person.
How does GHK bind copper?
IN VITRO — PHYSICAL CHEMISTRY
GHK stands for glycyl-L-histidyl-L-lysine, the three amino acids in the chain. The histidine residue in the middle is the key to copper binding: histidine contains a nitrogen-rich ring that readily coordinates metal ions, which is why the same residue appears in many of the body's own copper-handling proteins.
The defining chemistry paper used potentiometric titration and visible absorption spectrophotometry across a pH range of roughly 3.5 to 10.6 to work out which copper-peptide species form and in what proportions. That is the same class of technique used to characterise any metal-ligand system, and it is the reason the binding claim for GHK is on solid ground while many downstream claims are not. [1]
That same study reported something often left out of summaries. When GHK was placed in competition with albumin, the main copper-carrying protein in blood, at equal concentrations roughly 42% of the copper bound to the peptide. But at realistic physiological concentrations of copper, albumin, histidine and GHK together, only about 6% of copper was associated with low-molecular-weight components at all. In other words, in actual blood, albumin dominates copper handling and GHK is a minor participant. [1]
An earlier paper reported that GHK co-isolates from plasma with roughly equimolar copper and enhances copper uptake into cultured hepatoma cells. That is the origin of the description of GHK as a copper-delivery peptide, and it is a cell-culture finding, not a measurement in people. [2]
What do cells do in the presence of GHK-Cu?
IN VITRO — FIBROBLAST CULTURE
Fibroblasts are the cells in connective tissue that build and maintain the extracellular matrix, the scaffold of collagen and sugar-protein molecules that gives skin its structure. Most of the GHK-Cu literature is about what fibroblasts do when the complex is added to their culture medium.
| What was measured | Model | Reported finding |
|---|---|---|
| Collagen synthesis | Fibroblast culture | Stimulation from 10⁻¹² to 10⁻¹¹ M, maximal at 10⁻⁹ M, with no change in cell number |
| Sulfated glycosaminoglycan synthesis | Normal human fibroblasts | Dose-dependent increase, maximal at 10⁻⁹ to 10⁻⁸ M, returning toward control at higher concentrations |
| MMP-2 expression | Fibroblast culture | Increased MMP-2 protein and messenger RNA, alongside increased TIMP-1 and TIMP-2 secretion |
| Decorin and biglycan messenger RNA | Rat wound chambers and rat fibroblasts | Decorin messenger RNA increased, biglycan messenger RNA decreased |
The MMP result is the most interesting and the most often misreported. MMP-2 is a matrix metalloproteinase, an enzyme that breaks down extracellular matrix. TIMPs are tissue inhibitors of metalloproteinases, the body's own brake on those enzymes. GHK-Cu increased both in the same experiment. That is not a contradiction; it is the signature of remodelling rather than simple accumulation, where old matrix is being cleared at the same time as new matrix is laid down. Summaries that describe GHK-Cu as purely collagen-building omit half of what the study measured. [5]
Why does more not mean more?
IN VITRO — CONCENTRATION-RESPONSE DATA
Several of these studies report a biphasic concentration-response, meaning the effect rises with concentration up to a point and then falls away again rather than continuing to climb. Glycosaminoglycan synthesis was maximal between one and ten nanomolar and progressively returned to control levels at higher concentrations. Collagen synthesis peaked at one nanomolar. [3][4]
To put those numbers in perspective, one nanomolar is roughly one billionth of a mole per litre, an extremely dilute concentration. It is also a concentration achieved in a controlled culture dish where every cell is bathed evenly. It says nothing about what concentration would reach fibroblasts in intact skin, which is one of the central unresolved questions in this literature.
The original 1980 paper noted that GHK's effects at nanomolar concentrations ranged from growth stimulation to outright toxicity depending on the cell system used. Context-dependence of that kind is a reason for caution, not confidence. [2]
What about the gene-expression findings?
HUMAN TISSUE EXPRESSION ANALYSIS AND IN VITRO
A frequently cited 2012 study analysed gene expression across 64 tissue samples from eight lungs affected by emphysema, identified a gene signature associated with tissue destruction, then used a computational database screen to find compounds predicted to reverse that signature. GHK emerged from the screen, and the researchers then treated cultured human fibroblasts with it and observed expression changes consistent with the prediction, including effects on TGF-β pathway signalling, actin cytoskeleton organisation and integrin expression. [7]
That is a legitimate and interesting study, and it is routinely described in marketing material as though GHK had been shown to reverse lung disease. It was a tissue-expression and cell-culture study. No participant received GHK, and no clinical outcome was measured.
Claims that GHK modifies a large percentage of human genes derive from a computational connectivity-database analysis, not from a laboratory experiment measuring gene expression in treated humans.
Where does the mechanistic evidence stop?
- The mechanistic literature is dominated by two research groups and by review articles whose authors have declared commercial interests in the ingredient.
- Independent replication of the central fibroblast findings is limited.
- Effects are demonstrated at specific low concentrations in culture; the concentration reaching fibroblasts in intact skin after topical or other application has not been established in the indexed literature.
- No dedicated formal toxicology study of GHK-Cu was identifiable in the indexed literature.
- Widely circulated figures about plasma GHK concentrations declining with age, and a supposed meta-analysis of dozens of clinical trials, could not be traced to any indexed primary source and should not be repeated.
For what the collagen studies specifically measured, see GHK-Cu and collagen research.
Which species each study used is set out in GHK vs GHK-Cu.
Frequently Asked Questions
How does GHK bind copper?
The histidine residue in the middle of the tripeptide coordinates copper ions. The binding was characterised by potentiometric titration and absorption spectrophotometry across a wide pH range, establishing which copper-peptide species form and in what proportions.
Does GHK deliver copper into cells in the body?
A 1980 study showed GHK enhances copper uptake into cultured cells, and GHK co-isolates from plasma with copper. However, a detailed competition study found that at physiological concentrations albumin dominates copper binding, with only about 6% of copper associated with small molecules. The cell-culture finding has not been shown to translate to copper delivery in intact human tissue.
Why do studies use such low concentrations?
Because the measured effects peak at very low concentrations, typically around one nanomolar, and diminish at higher ones. Several studies report this biphasic pattern explicitly, with glycosaminoglycan synthesis returning toward control levels as concentration rises.
Has GHK-Cu been shown to work in humans?
No randomised controlled trial indexed in the major biomedical literature has demonstrated a skin or hair benefit from GHK-Cu with a validated endpoint. The mechanistic case rests on cell-culture and animal studies.
